MIB-626

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameMIB-626
Drug Alias NameMIB-626
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 2Acute Kidney Injury +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMetro International Biotech LLC
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalMetro International Biotech LLC
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 2Acute Kidney Injury +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A